Bavarian Nordic A/S (CPH:BAVA)(OTC: BVNRY), a biotechnology company focused on the development of innovative therapies against infectious diseases and cancer, announced on Thursday the submission by its partner, Janssen Pharmaceutical Companies of Johnson & Johnson, of Marketing Authorisation Applications (MAAs) to the European Medicines Agency (EMA) seeking licensure for an investigational Ebola vaccine regimen for the prevention of Ebola Virus Disease (EVD) caused by Zaire Ebola virus.
Reportedly, two MAAs have been submitted in parallel supporting each vaccine in the two-dose regimen (Ad26.ZEBOV, MVA-BN Filo). The EMA's Committee for Medicinal Products for Human Use (CHMP) granted an Accelerated Assessment in September 2019, which will shorten the review time for these applications.
This vaccine regimen includes Ad26.ZEBOV as the first dose, which is based on Janssen's AdVac technology, and MVA-BN Filo as the second dose, which is based on Bavarian Nordic's MVA-BN technology and is administered approximately eight weeks later.
These MAAs are supported by data from phase 1, 2 and 3 clinical studies evaluating the safety and immunogenicity of the vaccine regimen in adults and children, preclinical studies, and immunobridging analyses. To date, more than 6,500 volunteers across the US, Europe and Africa have participated in over 10 clinical studies of the vaccine.
Also, Janssen has ongoing discussions with the US Food and Drug Administration (FDA) to define the required data set for filing of the Ebola vaccine regimen under the FDA's Animal Rule licensure pathway and is also working in collaboration with the World Health Organisation (WHO) to enable registration of the Ebola vaccine regimen in African countries.
On 31 October 2019, Janssen announced that it will provide up to 500,000 regimens of its investigational vaccine to the Democratic Republic of Congo (DRC) for use in a new clinical trial organised by the DRC government and global health stakeholders in an effort to contain the country's Ebola outbreak.
Upon EMA approval of the MVA-BN Filo vaccine, Bavarian Nordic would be eligible to receive a milestone payment of USD10m under the licence agreement with Janssen.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories